Melanotan 2 Research

Melanotan 2 (MT-II) is a cyclic synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH). It acts as a potent, non-selective agonist at the MC1R, MC3R, MC4R and MC5R melanocortin receptors. MC2R, the ACTH receptor, primarily recognizes only ACTH peptides. Preclinical research has studied its effects on pigmentation via peripheral MC1R signaling in melanocytes, and on appetite regulation and sexual function via central melanocortin receptor activation. The receptor findings summarized here come from in vitro and animal studies. A separate section covers the small human record: three early studies from the group that designed the molecule and case reports of adverse events after unlicensed use.

This article explains what Melanotan 2 is, outlines its peptide structure, and summarizes preclinical receptor pharmacology of its interactions with melanocortin receptors. It is written for researchers and informed readers and focuses on receptor biology, structure, and preclinical findings, with a short account of the human record. It gives no guidance on use in people. Melanotan 2 is a research compound with no US approval.

What is Melanotan 2, and what it is not

Melanotan II explained simply: it is a small cyclic peptide designed as a more stable, more potent mimic of the body's own alpha-MSH. Before going further, it is worth clearing up two common points of confusion.

First, Melanotan 2 is not melatonin. Melatonin is an indoleamine hormone, N-acetyl-5-methoxytryptamine, produced by the pineal gland and associated with circadian timing. It is a different class of molecule with a different target biology, and the similarity in name is coincidental. Melanotan 2 is a peptide that acts on melanocortin receptors, not on melatonin receptors.

Second, Melanotan 2 is distinct from Melanotan 1. The difference between Melanotan 1 and 2 is structural. Melanotan 1 is the linear analog [Nle4, D-Phe7]-alpha-MSH, also called NDP-MSH or NDP-alpha-MSH, first reported by Sawyer and colleagues in 1980.^[1] It was later developed as the pharmaceutical afamelanotide. Melanotan 2 is a shorter cyclic analog developed afterward. Both are alpha-MSH analogs, but they differ in shape, receptor-selectivity profiles, and developmental paths, with Melanotan 2 remaining a research compound.

Melanotan 2 peptide structure

The Melanotan 2 peptide is a cyclic heptapeptide, written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The ring is closed by a lactam bridge between the side chains of the aspartate and lysine residues, which constrains the molecule into a defined three-dimensional shape. At its core is the conserved melanocortin message sequence His-Phe-Arg-Trp, the pharmacophore shared by the natural melanocortin peptides.

This design was part of a stepwise research process and serves as a useful case study in alpha-MSH analog research. The 1980 work on [Nle4, D-Phe7]-alpha-MSH replaced the oxidation-prone methionine at position 4 with norleucine, and the L-phenylalanine at position 7 with its D-isomer. That work showed the resulting analog resisted enzymatic degradation and exhibited greatly increased and prolonged activity in laboratory assays.

Moreover, Al-Obeidi and colleagues reported in 1989 that adding a cyclic lactam constraint, the basis of Melanotan 2, yielded potent, prolonged-acting analogs.^[2] The conformation of these analogs was rationalized using molecular dynamics. The cyclization is the structural feature that most distinguishes Melanotan 2 from the linear precursor.

The melanocortin system

Understanding the receptor context is important because Melanotan 2's activity depends on how the different melanocortin receptor subtypes respond to alpha-MSH analogs. As reviewed by Cone in 2006, the melanocortin system comprises five G protein-coupled receptors, MC1R to MC5R.^[3] It also includes peptide agonists cleaved from the proopiomelanocortin (POMC) precursor, namely the alpha, beta, and gamma forms of MSH and ACTH. The system further includes the endogenous antagonist proteins agouti and agouti-related protein.

The melanocortin receptors signal mainly through the stimulatory G protein (Gs), which activates adenylyl cyclase and raises intracellular cyclic AMP. The subtypes differ in their expression patterns and in the ligands they prefer. Notably, MC2R primarily recognizes only ACTH peptides.^[4]

Melanotan 2 mechanism of action

The mechanism of action of Melanotan 2 at the receptor level is that of a non-selective melanocortin receptor agonist. Of the five subtypes, MC1R, MC3R, MC4R, and MC5R all recognize alpha-MSH and its potent analogs.

The cyclic lactam scaffold that defines Melanotan 2 was first introduced as a series of potent, prolonged-acting agonists. Detailed structure-activity work on that scaffold by Hruby and colleagues showed that it engages MC1R, MC3R, MC4R and MC5R, with the unmodified D-Phe7 parent acting as an agonist, while bulky substitutions at position 7 convert it into a selective antagonist.^[4]

In practical terms, this means Melanotan 2 can engage and activate the MC1R, MC3R, MC4R, and MC5R subtypes rather than acting on a single receptor. The literature most frequently discusses Melanotan 2's MC1R and MC4R activities, but the breadth of activity across subtypes is itself a defining pharmacological feature. Upon binding, the agonist drives the same Gs to cyclic AMP signaling described above.

Structural biology of melanocortin receptor activation

Recent advances in structural biology have clarified how analogs of this class are recognized. In 2021, Zhang and colleagues reported cryo-electron microscopy structures of the human MC4R coupled to its Gs protein.^[5] In separate complexes, the receptor was bound to alpha-MSH, the linear analog afamelanotide, the cyclic lactam peptide bremelanotide, and the selective small-molecule agonist THIQ.

These structures showed that peptide agonists adopt a conserved binding mode within an open orthosteric pocket in the extracellular half of the receptor's seven-transmembrane bundle. They also identified a pair of toggle-switch residues that sense ligand binding and help determine the receptor's functional response. The work was built on an earlier finding by Yu and colleagues that a calcium ion serves as a cofactor for ligand binding at MC4R.^[6]

The study resolved both a linear analog (afamelanotide) and bremelanotide, which is Melanotan 2 with its C-terminal amide replaced by a free acid. Bremelanotide therefore carries the identical Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] lactam ring. For that reason, these structures provide a molecular picture directly relevant to how cyclic alpha-MSH analogs engage the receptor.

Melanotan 2 preclinical studies

Most foundational preclinical studies of Melanotan 2 focus on receptor and second-messenger pharmacology rather than whole-organism work. Historical potency assays for this peptide class, including amphibian melanophore bioassays and adenylyl cyclase activation in cultured melanoma cells, were used to quantify the extent to which the analogs activated melanocortin signaling.

The structural modifications introduced into Melanotan 2 are the norleucine and D-phenylalanine substitutions plus cyclization. Against these readouts, those modifications were shown to confer resistance to enzymatic breakdown and a longer duration of receptor activation than native alpha-MSH. Taken together, these studies present Melanotan 2 as a metabolically stable, conformationally constrained melanocortin agonist with activity across multiple receptor subtypes. Downstream physiological endpoints examined in animal models fall outside the scope of this receptor-focused article.

Human studies and reported harms

The human record for Melanotan 2 is small. All three published administration studies came from the University of Arizona group that designed the molecule, between 1996 and 2000.

In a single-blind, placebo-controlled pilot phase I study, Dorr and colleagues gave Melanotan 2 by injection to three healthy men, with saline as the placebo.^[7] Two of the three developed increased skin pigmentation. Mild nausea was reported at most dose levels, one man had somnolence and fatigue at the highest dose, and spontaneous penile erections followed dosing.

Two double-blind, placebo-controlled crossover studies followed, each in 10 men with erectile dysfunction: one group had no known organic cause, the other had organic risk factors.^[8][9] Penile rigidity was recorded for six hours after each injection. In both studies, the mean time at more than 80% tip rigidity was longer after Melanotan 2 than after placebo, and in the second study erections were reported after 12 of 19 Melanotan 2 injections versus 1 of 21 placebo injections.^[8][9] Nausea, yawning, and stretching were more frequent with the drug in both studies, and in the second, 4 of 19 injections were followed by severe nausea.^[8][9] A pooled report from the same group covers the same 20 men.^[10]

Outside trials, Melanotan 2 is sold online and used without a license, often for tanning, and case reports describe adverse events after this use, some of them serious. They include melanoma in a young woman who had combined injections with tanning-bed use,^[11] priapism, including a case that needed surgery when first-line treatment failed,^[12][13] systemic toxicity with rhabdomyolysis after a single large injection,^[14] new moles and darkening of existing ones, with changes that made moles hard to tell apart from melanoma,^[15][16][17] pigmentation of the oral mucosa after injections,^[18] and an oral mucosal melanoma after use of a nasal spray.^[19] Case reports show that these events followed use. They cannot show that Melanotan 2 caused them or how often such events occur.

Melanotan 2 has no US approval.^[20][22] FDA's page on bulk drug substances that may present significant safety risks in compounding lists Melanotan II among substances previously in category 2 whose nominations were later withdrawn. FDA notes a possible immunogenicity risk from aggregation or peptide-related impurities, and published case reports of serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism.^[21]

Research context and limitations

Several caveats shape how Melanotan 2 research should be interpreted. Its non-selectivity, while pharmacologically interesting, is a genuine limitation when the molecule is used as a research probe. Activating multiple receptor subtypes simultaneously makes it difficult to attribute any single effect to a specific receptor. This is one reason why later medicinal chemistry and the structural studies discussed above have pursued subtype-selective ligands.

The receptor-level data come from in vitro and animal pharmacology. The human data are three small studies from the group that designed the molecule, published between 1996 and 2000, and case reports, which cannot establish how often harms occur. Care should be taken not to extrapolate beyond these findings.

Conclusion

Melanotan 2 is best understood as a cyclic, stabilized alpha-MSH analog and a non-selective agonist of the MC1R, MC3R, MC4R, and MC5R subtypes. It is distinct from both melatonin and the linear Melanotan 1. The preclinical literature describing it is largely based on receptor-level pharmacology and, increasingly, structural biology.

The receptor findings above are not evidence of a clinical outcome in people. The human record is limited to three small early studies and case reports of adverse events after unlicensed use, some of them serious.

References

1. 1

   Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA. 1980;77(10):5754-8. doi:10.1073/pnas.77.10.5754. PMID 6777774.
2. 2

   Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged-acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. J Med Chem. 1989;32(12):2555-61. doi:10.1021/jm00132a010. PMID 2555512.
3. 3

   Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-49. doi:10.1210/er.2006-0034. PMID 17077189.
4. 4

   Hruby VJ, Lu D, Sharma SD, Castrucci AM, Kesterson RA, Al-Obeidi FA, et al. Cyclic lactam alpha-melanotropin analogues with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem. 1995;38(18):3454-61. doi:10.1021/jm00018a005. PMID 7658432.
5. 5

   Zhang H, Chen LN, Yang D. Structural insights into ligand recognition and activation of the melanocortin-4 receptor. Cell Res. 2021;31(11):1163-75. doi:10.1038/s41422-021-00552-3. PMID 34433901.
6. 6

   Yu J, Gimenez LE, Hernandez CC. Determination of the melanocortin-4 receptor structure identifies Ca2+ as a cofactor for ligand binding. Science. 2020;368(6489):428-33. doi:10.1126/science.aaz8995. PMID 32327598.
7. 7

   Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84. doi:10.1016/0024-3205(96)00160-9. PMID 8637402.
8. 8

   Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-93. PMID 9679884.
9. 9

   Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000;56(4):641-6. doi:10.1016/s0090-4295(00)00680-4. PMID 11018622.
10. 10

    Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-9. doi:10.1038/sj.ijir.3900582. PMID 11035391.
11. 11

    Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-6. doi:10.1159/000356389. PMID 24355990.
12. 12

    Mallory CW, Lopategui DM, Cordon BH. Melanotan tanning injection: a rare cause of priapism. Sex Med. 2021;9(1):100298. doi:10.1016/j.esxm.2020.100298. PMID 33460908.
13. 13

    Devlin J, Pomerleau A, Foote J. Melanotan II overdose associated with priapism. Clin Toxicol (Phila). 2013;51(4):383. doi:10.3109/15563650.2013.784775. PMID 23537392.
14. 14

    Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012;50(10):1169-73. doi:10.3109/15563650.2012.740637. PMID 23121206.
15. 15

    Schulze F, Erdmann H, Hardkop LH, Anemüller W, Rose C, Zillikens D, Fischer TW. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. Eur J Dermatol. 2014;24(1):107-9. doi:10.1684/ejd.2013.2227. PMID 24334249.
16. 16

    Burian E, Burian E. [Eruptive nevi after injection of drugs marketed as melanotan II. The first two Swedish cases described]. Lakartidningen. 2013;110(5):208-10. PMID 23451671. In Swedish.
17. 17

    Mang R, Krahl D, Assmann T. [Dermoscopic changes in melanocytic nevi during use of melanotan II]. Hautarzt. 2012;63(11):880-4. doi:10.1007/s00105-012-2420-1. PMID 23052015. In German.
18. 18

    Bonchev A. Changes in oral mucosa associated with Melanotan II injections: a case report. Life (Basel). 2026;16(2):265. doi:10.3390/life16020265. PMID 41752902.
19. 19

    Yassin Alsabbagh A, Bhujel N, Singh RP. Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? Int J Oral Maxillofac Surg. 2025;54(9):806-8. doi:10.1016/j.ijom.2025.03.014. PMID 40210573.
20. 20

    US Food and Drug Administration, Drugs@FDA. Query of api.fda.gov/drug/drugsfda.json on openfda.substance_name "MELANOTAN II" returned no match, 3 October 2026.
21. 21

    US Food and Drug Administration. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." Content current as of 22 April 2026, retrieved 3 October 2026; Melanotan II is listed in the table "Bulk drug substances nominated but withdrawn" (substances previously in category 2). fda.gov
22. 22

    US Food and Drug Administration. Warning letter to Tailor Made Compounding, LLC (MARCS-CMS 594743), 1 April 2020: Melanotan II is among the bulk drug substances the letter describes as not the subject of an applicable USP or NF monograph, not a component of an FDA-approved human drug, and not on the 503A bulks list. Retrieved 5 October 2026. fda.gov